U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
Go back to U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer| Bayer Aktiengesellschaft American Depositary Shares (AMEX: BAYRY) | Delayed: 13.76 -0.37 (2.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.13 | 52 Week High | $135.54 | |||
| Open | $13.89 | 52 Week Low | $94.36 | |||
| Day High | $13.91 | P/E | N/A | |||
| Day Low | $13.66 | EPS | $0.00 | |||
| Volume | 208,956 | |||||
| Bayer AG (AMEX: BAYZF) | Delayed: 55.00 -1.38 (2.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $56.38 | 52 Week High | $135.00 | |||
| Open | $55.00 | 52 Week Low | $94.95 | |||
| Day High | $55.00 | P/E | N/A | |||
| Day Low | $55.00 | EPS | $0.00 | |||
| Volume | 1,026 | |||||
